Low-renin hypertension in incidental adrenal adenomas and response to aldosterone-targeted therapy: a prospective study
- 27 June 2026
- journal article
- Published by Elsevier in European Journal of Internal Medicine
- p. 107042
Abstract
No abstract availableKeywords
Funding Information
- National Heart, Lung, and Blood Institute
- Agencia Nacional de Investigación y Desarrollo
This publication has 48 references indexed in Scilit:
- Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohortThe Lancet Diabetes & Endocrinology, 2025
- 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertensionEuropean Journal of Internal Medicine, 2024
- Primary Aldosteronism: A Pragmatic Approach to Diagnosis and ManagementMayo Clinic Proceedings, 2023
- Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort studyThe Lancet Diabetes & Endocrinology, 2020
- Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysisThe Lancet Diabetes & Endocrinology, 2018
- Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort studyThe Lancet Diabetes & Endocrinology, 2018
- Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohortThe Lancet Diabetes & Endocrinology, 2017
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trialThe Lancet, 2015
- LC–MS/MS Method for the Simultaneous Determination of Free Urinary SteroidsChromatographia, 2014
- A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive PatientsJACC, 2006